Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -148.02% is 238% below its 5-year average of 107.03%, around the middle of its 5-year range (-870.83%–477.03%).
32.70% above its 12-month average of -219.95%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -115.20%.
EBITDA MARGIN
-148.02%
EBITDA MARGIN AVG TTM
-219.95%
EBITDA MARGIN AVG 3Y
173.07%
EBITDA MARGIN AVG 5Y
107.03%
EBITDA MARGIN AVG 10Y
-100.44%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+32.70%
CURRENT VS 3Y AVG
-185.52%
CURRENT VS 5Y AVG
-238.29%
CURRENT VS 10Y AVG
-47.37%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
DarioHealth Corp.
Market Cap
$44.35M
EBITDA Margin
-148.02%
TTM Avg
-219.95%
3Y Avg
173.07%
5Y Avg
107.03%
Market Cap
$44.31M
EBITDA Margin
-131.42%
TTM Avg
-148.69%
3Y Avg
-221.80%
5Y Avg
-210.76%
Market Cap
$44.19M
EBITDA Margin
-89.16%
TTM Avg
-101.97%
3Y Avg
-124.94%
5Y Avg
-147.77%
Market Cap
$44.03M
EBITDA Margin
-376.33%
TTM Avg
-387.64%
3Y Avg
-608.18%
5Y Avg
-1395.53%
Market Cap
$45.21M
EBITDA Margin
-3807.96%
TTM Avg
-2001.11%
3Y Avg
-1442.90%
5Y Avg
-1442.90%
Market Cap
$42.97M
EBITDA Margin
-0.99%
TTM Avg
4.72%
3Y Avg
-25.09%
5Y Avg
-32.37%
Market Cap
$48.27M
EBITDA Margin
-11.13%
TTM Avg
-19.55%
3Y Avg
-13.57%
5Y Avg
-11.41%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| DarioHealth Corp. (DRIO) | $44.35M | -148.02% | -219.95% | 173.07% | 107.03% |
| Rapid Micro Biosystems, Inc. (RPID)vs › | $44.31M | -131.42% | -148.69% | -221.80% | -210.76% |
| CVRx, Inc. (CVRX)vs › | $44.19M | -89.16% | -101.97% | -124.94% | -147.77% |
| Nano-X Imaging Ltd. (NNOX)vs › | $44.03M | -376.33% | -387.64% | -608.18% | -1395.53% |
| Werewolf Therapeutics, Inc. (HOWL)vs › | $45.21M | -3807.96% | -2001.11% | -1442.90% | -1442.90% |
| BioStem Technologies, Inc. (BSEM)vs › | $42.97M | -0.99% | 4.72% | -25.09% | -32.37% |
| Precipio, Inc. (PRPO)vs › | $41.92M | 2.29% | -7.32% | -44.00% | -66.61% |
| Filana Therapeutics, Inc. (FLNA)vs › | $41.16M | N/A | N/A | N/A | N/A |
| Precision Optics Corporation, Inc. (POCI)vs › | $48.27M | -11.13% | -19.55% | -13.57% | -11.41% |
| Lite Strategy, Inc. (LITS)vs › | $48.68M | 22.86% | -25.83% | -102.29% | -102.29% |
Gross Margin
56.1%
EBITDA Margin
-148.0%
Operating Margin
-163.9%
Net Margin
322.8%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -115.20% |
| 2026-03-31 | -121.51% |
| 2025-12-31 | -870.83% |
| 2025-09-30 | -178.49% |
| 2025-06-30 | 186.29% |
| 2025-03-31 | 157.95% |
| 2024-12-31 | 187.07% |
| 2024-09-30 | 185.05% |
| 2024-06-30 | 288.23% |
| 2024-03-31 | 333.12% |
| 2023-12-31 | 429.62% |
| 2023-09-30 | 477.03% |
| 2023-06-30 | 247.71% |
| 2023-03-31 | 192.75% |
| 2022-12-31 | 150.68% |
| 2022-09-30 | 239.20% |
| 2022-06-30 | 300.23% |
| 2022-03-31 | 209.77% |
| 2021-12-31 | -344.91% |
| 2021-09-30 | -358.06% |
| 2021-06-30 | -325.87% |
| 2021-03-31 | 410.74% |
| 2020-12-31 | -433.37% |
| 2020-09-30 | -320.96% |
| 2020-06-30 | -228.15% |
| 2020-03-31 | -603.96% |
| 2019-12-31 | -230.03% |
| 2019-09-30 | -145.82% |
| 2019-06-30 | -314.05% |
| 2019-03-31 | -237.15% |
| 2018-12-31 | -300.47% |
| 2018-09-30 | -206.07% |
| 2018-06-30 | -275.81% |
| 2018-03-31 | -160.71% |
| 2017-12-31 | -194.99% |
| 2017-09-30 | -213.09% |
| 2017-06-30 | -335.54% |
| 2017-03-31 | -413.31% |
| 2016-12-31 | -443.91% |
| 2016-09-30 | -362.50% |
| 2016-06-30 | -378.77% |
| 2016-03-31 | -320.60% |
| 2015-12-31 | -576.30% |
| 2015-09-30 | -901.83% |
| 2015-06-30 | -816.00% |
| 2015-03-31 | -2534.33% |
| 2014-12-31 | -4886.27% |
